Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.

被引：0
|
作者：
Alessi, Joao Victor Machado
Ricciuti, Biagio
Aguilar, Elizabeth Jimenez
Hong, Fangxin
Wei, Zihan
Nishino, Mizuki
Plodkowski, Andrew J.
Sawan, Peter
Luo, Jia
Rizvi, Hira
Carter, Brett W.
Heymach, John
Altan, Mehmet
Hellmann, Matthew David
Awad, Mark M.
机构：
[1] Hosp Sirio Libanes, Sao Paulo, Brazil
[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Biostat Core, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[9] MD Anderson Canc Ctr, Houston, TX USA
[10] Massachusetts Gen Hosp, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9568
引用
收藏
页数：2
相关论文
共 50 条
  • [31] THREE-YEAR OUTCOMES WITH FIRST-LINE PEMBROLIZUMAB FOR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) WITH A VERY HIGH PD-L1 TUMOR PROPORTION SCORE (TPS) ≥ 90%
    Ricciuti, Biagio
    Alessi, Joao Victor
    Alden, Stephanie
    Lamberti, Giuseppe
    Vaz, Victor
    Barrichello, Adriana
    Sholl, Lynette
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A336 - A336
  • [32] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    CANCER RESEARCH, 2019, 79 (13)
  • [33] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
  • [34] First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
    Liu, Qiao
    Zhou, Zhen
    Luo, Xia
    Yi, Lidan
    Peng, Liubao
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [35] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [36] Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer
    Rossi, Sabrina
    Pagliaro, Arianna
    Finocchiaro, Giovanna
    Marinello, Arianna
    Giordano, Laura
    Bria, Emilio
    Stefani, Alessio
    Vitale, Antonio
    Toschi, Luca
    D'Argento, Ettore
    Santoro, Armando
    FUTURE ONCOLOGY, 2024, 20 (07) : 373 - 380
  • [37] Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer
    Nishino, Mizuki
    Hong, Fangxin
    Ricciuti, Biagio
    Hatabu, Hiroto
    Awad, Mark M.
    JCO PRECISION ONCOLOGY, 2021, 5 : 501 - 509
  • [38] Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold
    Zhijie Xu
    Xiang Wang
    Xi Chen
    Shuangshuang Zeng
    Zhicheng Gong
    Yuanliang Yan
    Journal of Cell Communication and Signaling, 2020, 14 : 129 - 130
  • [39] Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold
    Xu, Zhijie
    Wang, Xiang
    Chen, Xi
    Zeng, Shuangshuang
    Gong, Zhicheng
    Yan, Yuanliang
    JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2020, 14 (01) : 129 - 130
  • [40] Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
    Huang, Min
    Lopes, Gilberto de Lima
    Insinga, Ralph P.
    Burke, Thomas
    Ejzykowicz, Flavia
    Zhang, Ying
    Feliciano, Josephine L.
    IMMUNOTHERAPY, 2019, 11 (17) : 1463 - 1478
12345